Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study

Journal of Clinical Virology

Volumn 60, Issue 3, 2014, Pages 295-300

  Peters, Lars ^a   Neuhaus, Jacqueline ^b   Duprez, Daniel ^c   Neaton, James D ^b   Tracy, Russel ^d   Klein, Marina B ^e   Mocroft, Amanda ^f   Rockstroh, Jürgen ^g   Dore, Gregory ^h   Lundgren, Jens D ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Coagulation; Hepatitis; HIV; Inflammation; Microbial translocation

Indexed keywords

ANTIRETROVIRUS AGENT; ANTITHROMBIN III; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; C REACTIVE PROTEIN; CD14 ANTIGEN; D DIMER; HYALURONIC ACID; INTERLEUKIN 6; PROTEIN C; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR; ANTIVIRUS AGENT; AUTACOID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROBIAL TRANSLOCATION; MIXED INFECTION; PRIORITY JOURNAL; RANDOMIZATION; VIRAL PHENOMENA AND FUNCTIONS; BLOOD; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; TIME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; HYALURONIC ACID; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; TIME FACTORS; VIRAL LOAD;

EID: 84902139858     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.03.017     Document Type: Article

References (23)

1. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283-2296.
2. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5(10):e203.
3. Tedaldi E., Peters L., Neuhaus J., Puoti M., Rockstroh J., Klein M.B., et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008, 47(11):1468-1475.
4. Peters L., Neuhaus J., Mocroft A., Soriano V., Rockstroh J., Dore G., et al. Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther 2011, 16(5):667-675.
5. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12(12):1365-1371.
6. Funderburg N.T., Mayne E., Sieg S.F., Asaad R., Jiang W., Kalinowska M., et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010, 115(2):161-167.
7. Sandler N.G., Wand H., Roque A., Law M., Nason M.C., Nixon D.E., et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011, 203(6):780-790.
8. Violi F., Ferro D., Basili S., Saliola M., Quintarelli C., Alessandri C., et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology 1995, 109(2):531-539.
9. El Sadr W.M., Grund B., Neuhaus J., Babiker A., Cohen C.J., Darbyshire J., et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008, 149(5):289-299.
10. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001, 103(19):2323-2327.
11. Danesh J., Kaptoge S., Mann A.G., Sarwar N., Wood A., Angleman S.B., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008, 5(4):e78.
12. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
13. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321(7255):199-204.
14. Lee J.K., Bettencourt R., Brenner D., Le T.A., Barrett-Connor E., Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS ONE 2012, 7(4):e34218.
15. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
16. Coussens L.M. Nature 2002, 420(6917):860-867.
17. Jin X., Zimmers T.A., Perez E.A., Pierce R.H., Zhang Z., Koniaris L.G. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006, 43(3):474-484.
18. Johnson C., Han Y., Hughart N., McCarra J., Alpini G., Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012, 1(1):58-70.
19. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012, 52:199-219.
20. Caradonna L., Mastronardi M.L., Magrone T., Cozzolongo R., Cuppone R., Manghisi O.G., et al. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Des 2002, 8(11):995-1005.
21. Nunes D., Fleming C., Offner G., O'Brien M., Tumilty S., Fix O., et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005, 40(5):538-544.
22. Peters L., Mocroft A., Soriano V., Rockstroh J., Rauch A., Karlsson A., et al. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS ONE 2013, 8(5):e64283.
23. Halfon P., Bourliere M., Penaranda G., Deydier R., Renou C., Botta-Fridlund D., et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005, 4:6.